These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 516362)

  • 1. delta 9-Tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancerchemotherapy; a double-blind cross-over trial against placebo.
    Kluin-Neleman JC; Neleman FA; Meuwissen OJ; Maes RA
    Vet Hum Toxicol; 1979 Oct; 21(5):338-40. PubMed ID: 516362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting.
    Citron ML; Herman TS; Vreeland F; Krasnow SH; Fossieck BE; Harwood S; Franklin R; Cohen MH
    Cancer Treat Rep; 1985 Jan; 69(1):109-12. PubMed ID: 2981616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine.
    Sallan SE; Cronin C; Zelen M; Zinberg NE
    N Engl J Med; 1980 Jan; 302(3):135-8. PubMed ID: 6985702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol.
    Ekert H; Waters KD; Jurk IH; Mobilia J; Loughnan P
    Med J Aust; 1979 Dec; 2(12):657-9. PubMed ID: 231736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antiemetic activity of tetrahydrocannabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy.
    Colls BM; Ferry DG; Gray AJ; Harvey VJ; McQueen EG
    N Z Med J; 1980 Jun; 91(662):449-51. PubMed ID: 6250106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone.
    Liebman HA; Hum GJ; Sheehan WW; Ryden VM; Bateman JR
    Cancer Treat Rep; 1983 May; 67(5):413-9. PubMed ID: 6342771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy.
    Sallan SE; Zinberg NE; Frei E
    N Engl J Med; 1975 Oct; 293(16):795-7. PubMed ID: 1099449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma.
    Numbenjapon T; Sriswasdi C; Mongkonsritragoon W; Leelasiri A; Prayoonwiwat W
    J Med Assoc Thai; 2002 Nov; 85(11):1156-63. PubMed ID: 12546311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delta-9-tetrahydrocannabinol as an antiemetic.
    Anderson PO; McGuire GG
    Am J Hosp Pharm; 1981 May; 38(5):639-46. PubMed ID: 6269423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial.
    Müller-Vahl KR; Schneider U; Koblenz A; Jöbges M; Kolbe H; Daldrup T; Emrich HM
    Pharmacopsychiatry; 2002 Mar; 35(2):57-61. PubMed ID: 11951146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Polychemotherapy of lymphomas. Results of a selection of 32 cases diagnosed in stage III and stage IV and not previously treated].
    Neretto G; Giovanelli E; Agricola R; Furno F
    Minerva Med; 1978 Oct; 69(49):3367-71. PubMed ID: 724146
    [No Abstract]   [Full Text] [Related]  

  • 12. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
    Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term complications of MOPP chemotherapy in patients with Hodgkin's disease.
    Cunningham J; Mauch P; Rosenthal DS; Canellos GP
    Cancer Treat Rep; 1982 Apr; 66(4):1015-22. PubMed ID: 7074629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis.
    Steele N; Gralla RJ; Braun DW; Young CW
    Cancer Treat Rep; 1980; 64(2-3):219-24. PubMed ID: 6250699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytostatic therapy-induced vomiting inhibited by domperidone. A double-blind cross-over study.
    Hamers J
    Biomedicine; 1978 Nov; 29(7):242-4. PubMed ID: 371690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delta-9-tetrahydrocannabinol (THC) as an antiemetic.
    Kluin-Nelemans JC; Meuwissen OJ; Nelemans FA; Maes RA
    N Engl J Med; 1980 Jun; 302(24):1364-5. PubMed ID: 6246424
    [No Abstract]   [Full Text] [Related]  

  • 18. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group.
    ; Strasser F; Luftner D; Possinger K; Ernst G; Ruhstaller T; Meissner W; Ko YD; Schnelle M; Reif M; Cerny T
    J Clin Oncol; 2006 Jul; 24(21):3394-400. PubMed ID: 16849753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.